![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
9 min
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
Niki Karavitaki on the risk of brain tumours after radiotherapy for pituitary adenoma The Lancet Diabetes & Endocrinology in conversation with
-
- Medicin
Niki Karavitaki talks with The Lancet Diabetes & Endocrinology about the risk of a second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma.Read the full article:Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngiomaContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://you...
Niki Karavitaki talks with The Lancet Diabetes & Endocrinology about the risk of a second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma.Read the full article:Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngiomaContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://you...
9 min